Bronstein, Gewirtz & Grossman, LLC reminds investors who purchased or acquired Medpace Holdings, Inc. securities between April 22, 2025, and February 9, 2026, of the June 8, 2026 deadline to move for lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that defendants made false or misleading statements regarding the company's backlog cancellation rate and book-to-bill ratio, overstating the stability of its business and funding environment. Investors may seek compensation without out-of-pocket fees through a contingency fee arrangement.

The complaint contends that Medpace repeatedly portrayed an overly optimistic book-to-bill ratio of approximately 1.15 during earnings calls and other public communications, despite contrary internal information. These statements allegedly provided investors with overly positive growth expectations. On February 9, 2026, Medpace announced its fourth quarter 2025 book-to-bill ratio of 1.04, falling short of guidance. Following this announcement, the price of Medpace's common stock declined significantly.

Key Dates and Metrics

A class action lawsuit has already been filed. The court-appointed lead plaintiff is typically the investor with the largest financial interest in the relief sought by the class. Investors may choose to serve as lead plaintiff through counsel of their choice, select other counsel, or remain an absent class member. The decision to serve as lead plaintiff does not affect an investor's ability to share in any potential recovery. Until a class is certified, investors are not represented by counsel unless they retain one.